Helus Pharma's HLP004 Shows Meaningful Improvement for Difficult-to-Treat Generalized Anxiety Disorder
Market Chameleon (Thu, 5-Mar 7:57 AM)
HELUS Pharma Highlights Strong Cash Position and Advancing Clinical Milestones in Q3 2026
Market Chameleon (Tue, 17-Feb 11:44 AM)
Helus Pharma Appoints Industry Veteran Michael Cola as CEO—What This Leadership Shift Signals for Its Mental Health Pipeline
Market Chameleon (Tue, 10-Feb 9:20 AM)
